BZ019

非病毒载体CD19 CAR-T细胞（上海细胞治疗）

Report date: 2026/02/12 20:00:14

Base Information

Drug NameBZ019
Drug Alias Name非病毒载体靶向CD19嵌合抗原受体T细胞注射液（上海细胞治疗）靶向CD19的嵌合抗原受体T细胞注射液（上海细胞治疗）非病毒载体CD19 CAR-T细胞注射液（上海细胞治疗）BZ-019
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Cell Therapy Group Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Cell Therapy Group Co Ltd
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A